Seres Therapeutics, Inc. - Common Stock (MCRB)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 31, 2026Investment Snapshot
- Trading 74% below Graham Number ($34.48) — significant margin of safety
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 248.3% with 31,284.0% net margin
Seres Therapeutics, Inc. - Common Stock (MCRB) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $84 million . Key value metrics: P/E ratio 0.8, P/B ratio 1.91, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Seres Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
Seres Therapeutics, Inc. - Common Stock (MCRB) is trading 74% below its Graham Number of $34.48 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 0.8x.
On financial health, MCRB shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 248.3% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 2.49.
StockPik's composite Value Score for MCRB is 72/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
MCRB shows earnings growing at 4,088%.